Market Cap 176.50M
Revenue (ttm) 35.58M
Net Income (ttm) -105.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -296.01%
Debt to Equity Ratio 0.00
Volume 765,269
Avg Vol 2,219,164
Day's Range N/A - N/A
Shares Out 71.17M
Stochastic %K 58%
Beta 2.95
Analysts Strong Sell
Price Target $12.00

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
josegodoy
josegodoy Nov. 14 at 10:18 PM
$CCCC Apologies: estimated SIGNIFICANT move in about 1.5 months The anatomy of movement - H&S formation (either top or bottom) - MACD + signal line overlap = for approx 2.5-3 months, then MACD crosses over - moving averages: 20 day EMA crosses over the 50 day SMA - volume: the more the better (obviously) The weekly chart #1) H&S bottom (green circle) - MACD + signal overlap: approx 2.5 months - MACD crossover: +421% - the moving average crossover (green arrow): additional +64% - total move: +485% #2) H&S top (red circle) - MACD + signal overlap: approx 3.3 months - MACD cross & moving average cross happens about 2 weeks apart - total move: -79% #3) H&S bottom (current formation) - MACD + signal overlap: approx 1.3 months - moving averages converging to cross over (blue circle) An opinion
1 · Reply
josegodoy
josegodoy Nov. 14 at 5:04 PM
$CCCC I’m thinking 1.5-2.5 weeks we might see some movement
0 · Reply
lelongduzboob
lelongduzboob Nov. 13 at 10:46 PM
$CCCC so Wasatch Advisors LP joined the chat with 6,8% ownership
1 · Reply
BugHunti
BugHunti Nov. 13 at 12:38 PM
$CCCC should start moving
1 · Reply
merlin8121
merlin8121 Nov. 13 at 11:46 AM
$CCCC New report out : https://www.merlintrader.com/biotech-fury/
0 · Reply
lelongduzboob
lelongduzboob Nov. 12 at 9:43 PM
$CCCC 4,09M stocks at 2,48$ AM
1 · Reply
Stmkr
Stmkr Nov. 12 at 3:28 PM
$PRLD $CCCC $NRIX DACs the next big thing in oncology
1 · Reply
Nova_Trades
Nova_Trades Nov. 12 at 4:39 AM
Wednesday Watchlist — Pt. 2 $SONY, $CYCU, $NUVB, $CCCC, $SWAG watching for breakout continuation and strong follow-through on volume. 📊
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 12 at 3:13 AM
Money Wednesday Watchlist Pt. 9 $CYCU $NUVB $SWAG $CCCC $SONY Tomorrow should be Crazy after like a 1000% runner. Make sure yall ready. 📈😱
0 · Reply
lelongduzboob
lelongduzboob Nov. 10 at 9:02 PM
$CCCC Is this a Bullish Tri star?
1 · Reply
Latest News on CCCC
C4 Therapeutics, Inc. - Special Call

Sep 22, 2025, 5:23 AM EDT - 7 weeks ago

C4 Therapeutics, Inc. - Special Call


C4 Therapeutics: An Entry Point If There's Ever Going To Be One

Jun 16, 2025, 1:50 PM EDT - 5 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One


C4 Therapeutics Announces Chief Financial Officer Succession

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession


josegodoy
josegodoy Nov. 14 at 10:18 PM
$CCCC Apologies: estimated SIGNIFICANT move in about 1.5 months The anatomy of movement - H&S formation (either top or bottom) - MACD + signal line overlap = for approx 2.5-3 months, then MACD crosses over - moving averages: 20 day EMA crosses over the 50 day SMA - volume: the more the better (obviously) The weekly chart #1) H&S bottom (green circle) - MACD + signal overlap: approx 2.5 months - MACD crossover: +421% - the moving average crossover (green arrow): additional +64% - total move: +485% #2) H&S top (red circle) - MACD + signal overlap: approx 3.3 months - MACD cross & moving average cross happens about 2 weeks apart - total move: -79% #3) H&S bottom (current formation) - MACD + signal overlap: approx 1.3 months - moving averages converging to cross over (blue circle) An opinion
1 · Reply
josegodoy
josegodoy Nov. 14 at 5:04 PM
$CCCC I’m thinking 1.5-2.5 weeks we might see some movement
0 · Reply
lelongduzboob
lelongduzboob Nov. 13 at 10:46 PM
$CCCC so Wasatch Advisors LP joined the chat with 6,8% ownership
1 · Reply
BugHunti
BugHunti Nov. 13 at 12:38 PM
$CCCC should start moving
1 · Reply
merlin8121
merlin8121 Nov. 13 at 11:46 AM
$CCCC New report out : https://www.merlintrader.com/biotech-fury/
0 · Reply
lelongduzboob
lelongduzboob Nov. 12 at 9:43 PM
$CCCC 4,09M stocks at 2,48$ AM
1 · Reply
Stmkr
Stmkr Nov. 12 at 3:28 PM
$PRLD $CCCC $NRIX DACs the next big thing in oncology
1 · Reply
Nova_Trades
Nova_Trades Nov. 12 at 4:39 AM
Wednesday Watchlist — Pt. 2 $SONY, $CYCU, $NUVB, $CCCC, $SWAG watching for breakout continuation and strong follow-through on volume. 📊
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 12 at 3:13 AM
Money Wednesday Watchlist Pt. 9 $CYCU $NUVB $SWAG $CCCC $SONY Tomorrow should be Crazy after like a 1000% runner. Make sure yall ready. 📈😱
0 · Reply
lelongduzboob
lelongduzboob Nov. 10 at 9:02 PM
$CCCC Is this a Bullish Tri star?
1 · Reply
TwoThirdsProbablyDown
TwoThirdsProbablyDown Nov. 10 at 7:48 PM
$CCCC Any humans following this one? Cemsinomide data looked okay, but not the blockbuster protein degrader we hoped for. Is this page only bots?
2 · Reply
josegodoy
josegodoy Nov. 8 at 11:09 PM
$CCCC the bears are trying to work it but they seem to lack conviction Charts: simple line #1: daily - black horizontal line: $2.20 - in the 2nd should of the outlined heads and shoulder (H&S) formation, you can see the essence of a small H&S that is forming (~70%) from about mid-October into November. The intended/transient target: the lower red horizontal line (the neckline of the outlined H&S) - in the past, bears have been able to cut through the ascending slope (blue intermittent line). However, the “$2.20-$2.22 zone” was not there before + (currently the SMA 200 @ $2.18) #2: weekly - it should be noted that the bears did cut through the EMA (20) @ $2.38 (not shown here) - this chart shows an apparent lack of conviction (volume) - taking the previous 2 comments together, now is when bears have to push through the volume: H&S top completed + at the neckline + a (small) breach of the SMA (20) - at worse: They touch the horizontal red Line on the daily (IF) An opinion.
1 · Reply
zawojak
zawojak Nov. 8 at 3:50 PM
$CCCC either this or $HOWL hoping for a run shortly 🤞
0 · Reply
josegodoy
josegodoy Nov. 8 at 11:58 AM
$CCCC updated
1 · Reply
zawojak
zawojak Nov. 7 at 10:14 AM
$CCCC Barclays analyst Darout maintained a Buy rating on C4 Therapeutics today and set a price target of $10.00. Darout is a 5-star analyst with an average return of 23.7% and a 54.75% success rate. Darout covers the Healthcare sector, focusing on stocks such as Exelixis, Terns Pharmaceuticals, and Merus.
1 · Reply
d_risk
d_risk Nov. 6 at 4:37 PM
$CCCC - C4 Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors CCCC’s latest 10-Q flags heightened financial and dilution risks after a $117M raise, expanded capital needs for clinical trials and commercialization, ongoing losses, early-stage uncertainty, clinical and regulatory hurdles for its TORPEDO platform, patient enrollment and combination therapy challenges, and new warnings on stock volatility, liquidity, analyst coverage, insider control, and exposure to market and operational disruptions. #Biotechnology #StockVolatility #RegulatoryChallenges #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/CCCC/10-Q/2025-11-06
4 · Reply
Andysss
Andysss Nov. 6 at 1:01 PM
$CCCC «Boaring ER” but they are loaded and on track
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 6 at 12:26 PM
$CCCC $325 million pro forma cash. current mc is $225 million. 😉
0 · Reply
hk042
hk042 Nov. 6 at 12:09 PM
$CCCC beat! but no movement atm werid
1 · Reply
Andysss
Andysss Nov. 6 at 9:58 AM
$CCCC ER today?
1 · Reply
lelongduzboob
lelongduzboob Nov. 6 at 2:56 AM
$CCCC Using an ARIMA machine learning model and publicly available historical data since 2020, I have generated predictions for Q3 2025. The revenue prediction for Q3 2025 is 7.87 million USD, and the EPS prediction for Q3 2025 is -0.38.
0 · Reply
datapoint1728
datapoint1728 Nov. 5 at 11:42 PM
$CCCC New filing: FYI.
2 · Reply